Media Centre
SynOx Therapeutics secures up to $35m debt financing with Hercules Capital to progress development and commercialisation of emactuzumab
Tuesday April 30, 2024
Read MorePress Releases
SynOx Therapeutics secures up to $35m debt financing with Hercules Capital to progress development and commercialisation of emactuzumab
Tuesday April 30, 2024
SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT
Monday April 22, 2024
Emactuzumab designated as an Orphan Medicinal Product in Europe
Wednesday August 31, 2022
SynOx Therapeutics to present two posters at CTOS 2021 virtual Annual Meeting
Friday November 12, 2021
SynOx Therapeutics Further Strengthens Team with Appointments of Chief Medical Officer and Chief Technology Officer
Tuesday August 3, 2021
SynOx Therapeutics Strengthens Team with appointment of Ton Logtenberg as Chairman and Ray Barlow as Chief Executive Officer
Tuesday July 27, 2021
SynOx Therapeutics raises €37M in Series A Financing
Friday December 4, 2020
Publications
Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour
Tuesday December 1, 2020
CSF1R inhibition with emactuzumab in locally advanced diff use-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study
Monday July 13, 2015
